Gradient Denervation Technologies is a Paris-based medical device startup that focuses on the development of a unique, minimally invasive ultrasound-based catheter. This device is designed to treat heart failure patients who also suffer from pulmonary hypertension, a condition characterized by high blood pressure in the arteries of the lungs. The company's innovative therapeutic approach aims to improve cardiovascular health.

The company's target market includes patients suffering from Group 2 pulmonary hypertension, which is heart failure accompanied by high pulmonary vascular resistance. The company's business model revolves around the development, clinical testing, and eventual commercialization of its novel catheter-based system.

Gradient Denervation Technologies recently closed a €14m Series A funding round led by Sabadell Asabys, with participation from Thuja Capital and founding investor Sofinnova Partners. These funds will be used to advance the clinical development of the company's device.

The company has already enrolled its first patient in a first-in-human clinical study, marking a significant milestone in its journey. The company is led by CEO Martin Grasse, a veteran with over 15 years in the medical device industry.

In summary, Gradient Denervation Technologies is a promising startup in the medical device sector, with a focus on improving the lives of heart failure patients with associated pulmonary hypertension. Its innovative, minimally invasive device has the potential to revolutionize treatment in this area.

Keywords: Medical Device, Heart Failure, Pulmonary Hypertension, Minimally Invasive, Catheter, Cardiovascular Health, Clinical Development, Series A Funding, First-in-Human Study, Paris-based Startup.